In KEYNOTE-061, pembrolizumab did not significantly improve OS compared with paclitaxel as second-line therapy for metastatic GC with PD-L1 CPS ≥ 1 (median OS was 9.1 months with pembrolizumab and 8.3 months with paclitaxel) [20]. This evidence concerns the gene CD274 and gastric cancer.